vs
Side-by-side financial comparison of Arcellx, Inc. (ACLX) and AMREP CORP. (AXR). Click either name above to swap in a different company.
AMREP CORP. is the larger business by last-quarter revenue ($14.6M vs $8.1M, roughly 1.8× Arcellx, Inc.). AMREP CORP. runs the higher net margin — 21.6% vs -766.0%, a 787.6% gap on every dollar of revenue. On growth, AMREP CORP. posted the faster year-over-year revenue change (93.8% vs -79.3%). AMREP CORP. produced more free cash flow last quarter ($5.4M vs $-63.9M). Over the past eight quarters, AMREP CORP.'s revenue compounded faster (-13.6% CAGR vs -24.6%).
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.
ACLX vs AXR — Head-to-Head
Income Statement — Q1 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $14.6M |
| Net Profit | $-62.3M | $3.1M |
| Gross Margin | — | — |
| Operating Margin | -847.6% | 20.6% |
| Net Margin | -766.0% | 21.6% |
| Revenue YoY | -79.3% | 93.8% |
| Net Profit YoY | -765.1% | 338.9% |
| EPS (diluted) | $-1.13 | $0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.6M | ||
| Q4 25 | — | $9.4M | ||
| Q3 25 | — | $17.9M | ||
| Q2 25 | — | $11.2M | ||
| Q1 25 | $8.1M | $7.5M | ||
| Q4 24 | $15.3M | $11.9M | ||
| Q3 24 | $26.0M | $19.1M | ||
| Q2 24 | $27.4M | $19.5M |
| Q1 26 | — | $3.1M | ||
| Q4 25 | — | $1.2M | ||
| Q3 25 | — | $4.7M | ||
| Q2 25 | — | $3.9M | ||
| Q1 25 | $-62.3M | $717.0K | ||
| Q4 24 | $-47.1M | $4.0M | ||
| Q3 24 | $-25.9M | $4.1M | ||
| Q2 24 | $-27.2M | $4.1M |
| Q1 26 | — | 20.6% | ||
| Q4 25 | — | 11.9% | ||
| Q3 25 | — | 34.4% | ||
| Q2 25 | — | 31.7% | ||
| Q1 25 | -847.6% | 5.7% | ||
| Q4 24 | -348.2% | 26.4% | ||
| Q3 24 | -129.1% | 26.1% | ||
| Q2 24 | -127.8% | 23.9% |
| Q1 26 | — | 21.6% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | — | 26.3% | ||
| Q2 25 | — | 34.8% | ||
| Q1 25 | -766.0% | 9.5% | ||
| Q4 24 | -308.4% | 33.9% | ||
| Q3 24 | -99.4% | 21.3% | ||
| Q2 24 | -99.3% | 21.2% |
| Q1 26 | — | $0.58 | ||
| Q4 25 | — | $0.22 | ||
| Q3 25 | — | $0.87 | ||
| Q2 25 | — | $0.73 | ||
| Q1 25 | $-1.13 | $0.13 | ||
| Q4 24 | $-0.87 | $0.75 | ||
| Q3 24 | $-0.48 | $0.76 | ||
| Q2 24 | $-0.51 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $543.3M | $50.0M |
| Total DebtLower is stronger | — | $21.0K |
| Stockholders' EquityBook value | $416.9M | $139.4M |
| Total Assets | $648.1M | $143.9M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $50.0M | ||
| Q4 25 | — | $44.6M | ||
| Q3 25 | — | $48.9M | ||
| Q2 25 | — | $39.5M | ||
| Q1 25 | $543.3M | $36.9M | ||
| Q4 24 | $587.4M | $40.1M | ||
| Q3 24 | $574.3M | $40.4M | ||
| Q2 24 | $516.7M | $29.7M |
| Q1 26 | — | $21.0K | ||
| Q4 25 | — | $23.0K | ||
| Q3 25 | — | $25.0K | ||
| Q2 25 | — | $26.0K | ||
| Q1 25 | — | $29.0K | ||
| Q4 24 | — | $32.0K | ||
| Q3 24 | — | $34.0K | ||
| Q2 24 | — | $35.0K |
| Q1 26 | — | $139.4M | ||
| Q4 25 | — | $136.0M | ||
| Q3 25 | — | $134.7M | ||
| Q2 25 | — | $130.0M | ||
| Q1 25 | $416.9M | $126.0M | ||
| Q4 24 | $454.8M | $125.1M | ||
| Q3 24 | $483.0M | $122.2M | ||
| Q2 24 | $487.2M | $118.0M |
| Q1 26 | — | $143.9M | ||
| Q4 25 | — | $140.1M | ||
| Q3 25 | — | $140.7M | ||
| Q2 25 | — | $133.8M | ||
| Q1 25 | $648.1M | $128.9M | ||
| Q4 24 | $711.3M | $129.1M | ||
| Q3 24 | $764.9M | $127.0M | ||
| Q2 24 | $734.3M | $122.8M |
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.1M | $5.4M |
| Free Cash FlowOCF − Capex | $-63.9M | $5.4M |
| FCF MarginFCF / Revenue | -786.4% | 37.0% |
| Capex IntensityCapex / Revenue | 9.6% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $-122.5M | $20.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.4M | ||
| Q4 25 | — | $-4.3M | ||
| Q3 25 | — | $9.5M | ||
| Q2 25 | — | $10.2M | ||
| Q1 25 | $-63.1M | $-3.2M | ||
| Q4 24 | $-46.0M | $-182.0K | ||
| Q3 24 | $30.7M | $10.7M | ||
| Q2 24 | $-36.2M | $10.7M |
| Q1 26 | — | $5.4M | ||
| Q4 25 | — | $-4.3M | ||
| Q3 25 | — | $9.5M | ||
| Q2 25 | — | $9.7M | ||
| Q1 25 | $-63.9M | $-3.3M | ||
| Q4 24 | $-47.5M | $-268.0K | ||
| Q3 24 | $28.4M | $10.7M | ||
| Q2 24 | $-39.5M | $10.3M |
| Q1 26 | — | 37.0% | ||
| Q4 25 | — | -45.9% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 86.4% | ||
| Q1 25 | -786.4% | -43.4% | ||
| Q4 24 | -311.3% | -2.3% | ||
| Q3 24 | 109.2% | 55.8% | ||
| Q2 24 | -144.1% | 52.5% |
| Q1 26 | — | 0.1% | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | 9.6% | 0.3% | ||
| Q4 24 | 9.8% | 0.7% | ||
| Q3 24 | 8.8% | 0.2% | ||
| Q2 24 | 11.7% | 2.3% |
| Q1 26 | — | 1.72× | ||
| Q4 25 | — | -3.54× | ||
| Q3 25 | — | 2.03× | ||
| Q2 25 | — | 2.63× | ||
| Q1 25 | — | -4.51× | ||
| Q4 24 | — | -0.05× | ||
| Q3 24 | — | 2.63× | ||
| Q2 24 | — | 2.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
